Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in EGFR-Positive Triple-Negative Breast Cancer
NCT00597597Phase 2Terminated
- Sponsor
- Rush University Medical Center
- Start
- Apr 2007
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer, sponsored by Rush University Medical Center. Primary endpoint: Progression Free Survival at 6 months. Started Apr 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00597597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597597.